EKTERLY

This brand name is authorized in United States. It is also authorized in Austria, Estonia, Italy, Lithuania.

Active ingredients

The drug EKTERLY contains one active pharmaceutical ingredient (API):

1	Sebetralstat UNII O5ZD2TU2B7 - SEBETRALSTAT
	Sebetralstat is a competitive, reversible inhibitor of plasma kallikrein (PKa). By inhibiting PKa, sebetralstat blocks the cleavage of high molecular weight kininogen (HK) and the subsequent generation of bradykinin (BK), thereby halting HAE attack progression which is associated with increased vascular permeability and oedema formation. Sebetralstat also suppresses the activation of positive feedback mechanism of the kallikrein-kinin system (KKS), thereby reducing factor XIIa (FXIIa) and additional PKa production.
	Read more about Sebetralstat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EKTERLY Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
EKTERLY Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B06AC08		B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AC Drugs used in hereditary angioedema
Discover more medicines within B06AC08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3131817, 3131828
IT	Agenzia del Farmaco	052563018, 052563020
LT	Valstybinė vaistų kontrolės tarnyba	1104928, 1104929
US	FDA, National Drug Code	82928-300